Beyond one-sizes-fits-all: the promise and pitfalls of stratified medicine in tuberculosis
Year: 2026
Type: editorial
Abstract: Tuberculosis remains the leading cause of death from a single infectious disease worldwide, and drug-resistant forms continue to threaten global control efforts. 1 Recent years have witnessed a major revolution in the treatment of drug-resistant tuberculosis, with the introduction of several shorter, all-oral regimens. Yet, these approaches remain largely standardized, with little consideration of individual disease characteristics.
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,780
Awards: G1592931069, G1803181862, G4372699042, G4971071931, Point-of-care pharmacogenomic testing to optimize isoniazid dosing for tuberculosis prevention, University of California San Francisco - to develop a translational understanding of TB drug regimen efficacy from pre-clinical studies to clinical outcomes, University of California San Francisco - to update the findings of TB ReFLECT to inform late stage TB regimen trial design, University of Colorado Denver - to improve selection and clinical evaluation of novel PAN-TB TB drug regimens, Diagnosis of tuberculosis and monitoring of treatment via RNA liquid biopsy, Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium
OpenAlex ID: W7203501310
